Last reviewed · How we verify
rabeprazole-based triple therapy
rabeprazole-based triple therapy is a Small molecule drug developed by Kaohsiung Medical University. It is currently FDA-approved. Also known as: Pariet-based triple therapy.
Rabeprazole is a small molecule proton pump inhibitor used in triple therapy for Helicobacter pylori eradication, often combined with antibiotics such as amoxicillin. This triple therapy is studied in clinical trials, including one titled "Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication" (NCT06349486).
At a glance
| Generic name | rabeprazole-based triple therapy |
|---|---|
| Also known as | Pariet-based triple therapy |
| Sponsor | Kaohsiung Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
- Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study (NA)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD (PHASE3)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy (PHASE4)
- Tailored Juice-guided Eradication Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rabeprazole-based triple therapy CI brief — competitive landscape report
- rabeprazole-based triple therapy updates RSS · CI watch RSS
- Kaohsiung Medical University portfolio CI
Frequently asked questions about rabeprazole-based triple therapy
What is rabeprazole-based triple therapy?
Who makes rabeprazole-based triple therapy?
Is rabeprazole-based triple therapy also known as anything else?
What development phase is rabeprazole-based triple therapy in?
Related
- Manufacturer: Kaohsiung Medical University — full pipeline
- Also known as: Pariet-based triple therapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing